Global Hepatitis Drugs Market
Overview:
Hepatitis is a liver infection that causes inflammation. Hepatitis A, B, C, D, and E are viral illnesses of the liver that are classed as hepatitis. Hepatitis A is a short-term, acute infection, but hepatitis B, C, and D are more likely to develop chronic. Hepatitis E is typically severe, but it is more harmful in pregnant women because it increases maternal and fetal death and morbidity.
The global hepatitis drugs market is expected to expand at a CAGR of 3.2% during the forecast period (2019–2027).
To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/2977
Drivers:
High prevalence of hepatitis is expected to propel growth of the global hepatitis drugs market over the forecast period. For instance, According to WHO estimates, 257 million people worldwide were living with chronic hepatitis B infection in 2015, and 8, 87, 000 individuals died as a result of hepatitis B.
Moreover, increasing initiatives by governments to increase drug coverage is also expected to boost growth of the global hepatitis drugs market. For instance, The Ontario Ministry of Health and Long-Term Care declared in 2018 that all patients, regardless of disease severity, are eligible for the Ontario Drug Benefit (ODP). As a consequence of successful talks among provinces and drug makers, Thunder Bay Group, a firm that provides HIV/AIDS/Hepatitis C education and support services, expands its presence into drugs in the same year.
Opportunities
R&D in hepatitis is expected to offer lucrative growth opportunities for players in the global hepatitis drugs market. Direct acting antivirals (DAAs), which facilitate the development of highly effective, INF-free hepatitis C medications, are driving the growth of the hepatitis drugs industry. Dual and triple DDA combinational treatments against the hepatitis C virus are in the pipelines of market companies.
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/2977
In the treatment of hepatitis C, a combination of drugs is more beneficial than a single regimen. For instance, Gilead submitted a new medication application to the FDA in 2016 for a fixed-dose combination of SOF/VEL/voxilaprevir for the treatment of HCV genotypes 1–6. Similarly, the European Medicines Agency awarded medicinal approval to the SOF/VEL/voxilaprevir combo in January 2017.
The Ministry of Health and Family Welfare, Government of India also inaugurated the National Viral Hepatitis Control Program on July 28, 2018 (World Hepatitis Day). It is a comprehensive project in India to prevent and manage viral hepatitis in order to meet the Sustainable Development Goal (SDG) of ending viral hepatitis by 2030.
Key Players:
Major players active in the global hepatitis drugs market are Bristol Myers Squibb Company, Merck & Co. Inc., LAURUS Labs, Gilead Sciences Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Cipla Inc, Zydus Cadila, Hetero Healthcare Limited, and GlaxoSmithKline PLC .
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/2977
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Landscape
- Epidemiology Analysis
- Reimbursement Scenario
- PEST Analysis
- Market Dynamics
- Global Hepatitis Drugs Market, By Drug Class, 2019 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Interferon Alphas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- HIV NRTIs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Hepatitis C Protease / NS5A Inhibitor Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleotide Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Nucleoside Analogue Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Thrombopoiesis Stimulating Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Disease Type, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hepatitis B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Route of Administration, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
- Global Hepatitis Drugs Market, By Distribution Channel, 2019 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Million)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/hepatitis-drugs-market-to-surpass-us-271801-million-by-2027-1827
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837